TCR-alpha/beta and CD19 depletion and treosulfan-based conditioning regimen in unrelated and haploidentical transplantation in children with acute myeloid leukemia

Bone Marrow Transplantation
M MaschanAlexei Maschan

Abstract

We evaluated the depletion of TCR-alpha/beta cells from the graft of children with high-risk AML, who received transplantation from unrelated (n=20) and haploidentical donors (n=13). The preparative regimen included treosulfan, melphalan, fludarabine and anti-thymocyte globulin. Grafts were PBSC engineered by TCR-alpha/beta and CD19 depletion. The graft contained a median of 9 × 10(6)/kg of CD34+ and 20 × 10(3)/kg of αβ-T cells. Post-transplant immune suppression included tacrolimus till day +30 and Mtx in 21 patients, tacrolimus in 5, Mtx in 2 and no prophylaxis in 5 patients. Sixteen patients received native or TCR-alpha/beta-depleted donor lymphocytes at a median of 47 (40-204) days. Median follow-up is 1.76 years. Primary engraftment was achieved in 33 patients (100%). Cumulative incidence of acute GvHD (aGvHD) grade 2-3 was 39 (26-60)%, half of them had skin-only aGvHD. Cumulative incidence of chronic GvHD was 30(18-50)%. Transplant-related mortality is 10(4-26)%. Event-free survival (EFS) is 60(43-76)% and overall survival (OS) is 67(50-84)% at 2 years. In a subgroup of patients, who received transplantation in CR, EFS is 66(48-84)% and OS-72(53-90)% at 2 years. Our data suggest that TCR-alpha/beta and CD19 depletion is a...Continue Reading

References

Jun 18, 1999·Annals of the New York Academy of Sciences·R HandgretingerT Klingebiel
Jul 17, 2012·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Elias Hallack AttaEliana Abdelhay
Aug 21, 2012·Annals of the New York Academy of Sciences·Lena OevermannRupert Handgretinger
Dec 5, 2012·Seminars in Oncology·Rupert Handgretinger
Apr 10, 2013·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Michael J BurkeMichael R Verneris
May 31, 2013·British Journal of Haematology·Claire BoothPaul Veys
Jul 30, 2014·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Arjan C LankesterUNKNOWN Westhafen Intercontinental Group
Sep 30, 2014·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Antonio Di StasiStefan O Ciurea
Feb 3, 2015·Bone Marrow Transplantation·J R PasswegUNKNOWN European Society for Blood and Marrow Transplantation (EBMT)

❮ Previous
Next ❯

Citations

Mar 28, 2017·Annals of Hematology·Ivan Sergeevich MoiseevBoris Vladimirovich Afanasyev
Feb 6, 2018·Current Stem Cell Reports·Moniek A de WitteJeffrey S Miller
Jan 24, 2018·Blood·Rupert Handgretinger, Karin Schilbach
Oct 27, 2018·Current Treatment Options in Oncology·Rebecca Levin-EpsteinGary Schiller
Nov 27, 2018·Pharmaceutical Development and Technology·Ibrahim El-SerafiJonas Mattsson
May 10, 2019·Expert Review of Clinical Immunology·Reem ElfekyPaul Veys
Jul 5, 2019·Pediatric Transplantation·Richard MitchellChris Fraser
Aug 5, 2017·Blood·Michael Uhlin
Jun 1, 2018·Journal of Immunology Research·Melissa Mavers, Alice Bertaina
Nov 30, 2016·Frontiers in Immunology·Monica ReisAnne Richter
Jul 5, 2017·Biomedicines·Haitham AbdelhakimAyman Saad
Feb 12, 2021·Blood Advances·Moniek A de WitteJürgen Kuball
Jan 14, 2020·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Erin GatzaSung Won Choi
Jun 29, 2021·Frontiers in Immunology·Priscila Ferreira SlepickaAlice Bertaina
Jan 25, 2019·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Larisa ShelikhovaMichael Maschan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.